Ligand-based pharmacophore detection, screening of potential pharmacophore and docking studies, to get effective glycogen synthase kinase inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 11, 2013, Pages 5504-5535

  Agrawal, Ritesh ^a   Jain, Pratima ^a   Dikshit, Subodh Narayan ^a   Bahare, Radhe Shyam ^b   Ganguly, Swastika ^b  

^a GOVERNMENT SCIENCE COLLEGE   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Diabetes Type II; Docking; Emerging targets; GSK 3; Pharmacophore; PharmaGist; ZincPharmer

Indexed keywords

2 (ETHYLSULFANYL) 3H,4H IMIDAZO[4,5 B]INDOLE; 2 IODO 6H INDOLO[2,3 B]QUINOXALINE 5,11 DIIUM 5,11 BIS(OLATE); [(2 (ETHYLSULFANYL) 3H 4H IMIDAZO[4, 5 B]INDOLE)]; [2 1 [[(6 FLUORO 1H 1,3 BENZODIAZOL 4 YL)CARBONYL]PYRROLIDIN 2 YL] 6 METHYL 1H,1,3 BENZODIAZOLE]; [2 [[ETHYL[(4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)METHYL]AMINO]METHYL]IMIDAZO[1,2 A]PYRIDIN 1 IUM]; [2 NITRO 6H INDOLO[2,3 B]QUINOXALINE 5,11 DIIUM 5,11 BIS(OLATE)]; [4 1 [2 (5 METHYL 1H 1, 3BENZODIAZOL 2 YL)PIPERIDIN 1 YL] 1 OXOPROPAN 2 YL] 1, 2 DIHYDROPHTHALAZIN 1 ONE; [4 4 (1H 1,3 BENZODIAZOL 2 YL) 1H,4H,5H,6H,7H IMIDAZO[4,5 C]PYRIDIN 3 IUM 5 YL]; [5 (1H 1,3 BENZODIAZOL 2 YLMETHYL) 4 (4 METHYL 1H IMIDAZOL 5 YL) 1H,4H,5H,6H,7H IMIDAZO[4,5 C]PYRIDIN 3 IUM]; [8 METHYL 2 (((4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL)METHYL)(PROPAN 2 YL)AMINO)METHY IMIDAZO[1, 2 A]PYRIDIN 1 IUM]; ANTIDIABETIC AGENT; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; MALEIMIDE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; STAUROSPORINE; UNCLASSIFIED DRUG; ZINC;

ANTIDIABETIC ACTIVITY; ARTICLE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; VIRTUAL REALITY;

EID: 84887483151     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-013-0547-y     Document Type: Article

References (19)

1. Carlson HA, Masukawa KM, Rubins K, Bushman FD, Jorgensen WL, Lins RD, Briggs JM, McCammon JA (2000) Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem 43:2100-2114
2. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789. doi: 10.1038/378785a0 [doi]
3. Dorronsoro I, Castro A, Martinez A (2002) Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? Expert Opin Ther Pat 12(10):1527-1531
4. Dror O, Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2009) Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf Model 49:2333-2343. doi: 10.1021/ci900263d
5. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749. doi: 10.1021/jm0306430
6. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196. doi: 10.1021/jm051256o
7. Hayes JM, Stein M, Weiser JÃ (2004) Accurate calculations of ligand binding free energies: chiral separation with enantioselective receptors. J Phys Chem A 108:3572-3580. doi: 10.1021/jp0373797
8. Horvath D (2008) Chemoinformatics and computational chemical biology, 672nd edn. Springer, New York, pp 261-298
9. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236. doi: 10.1021/ja9621760
10. Kubinyi H et al (2012) Drug discovery case studies. http://www.kubinyi. de/erlangen-07-05.pdf. Accessed 23 March 2012
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25. doi: 10.1016/S0169-409X(96)00423-1
12. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26
13. Marchand B, Tremblay I, Cagnol S, Boucher MJ (2012) Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 33:529-537. doi: 10.1093/carcin/bgr309
14. Nemoto T, Yanagita T, Kanai T, Wada A (2009) Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: the role of GSK-3beta in the maintenance of steady-state levels of insulin receptor signaling molecules and Na(v)1.7 sodium channel in adrenal chromaffin cells. J Pharmacol Sci 109:157-161
15. Santilli AA, Scotese AC, Tomarelli RM (1974) A potent antihypercholesterolemic agent: (4-chloro-6-(2, 3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643). Experientia 30:1110-1111
16. Schneidman-Duhovny D, Dror O, Inbar Y, Nussinov R, Wolfson HJ (2008) Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules. J Comput Biol 15:737-754. doi: 10.1089/cmb.2007.0130
17. Shatsky M, Shulman-Peleg A, Nussinov R, Wolfson HJ (2006) The multiple common point set problem and its application to molecule binding pattern detection. J Comput Biol 13:407-428. doi: 10.1089/cmb.2006.13.407
18. Tanabe K, Liu Z, Patel S, Doble BW, Li L, Cras-Meneur C, Martinez SC, Welling CM, White MF, Bernal-Mizrachi E, Woodgett JR, Permutt MA (2008) Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol 6:e37. doi: 10.1371/journal.pbio.0060037
19. Wada A (2009) GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14:1558-1570